Maj-Britt Kaltoft

Corporate Officer/Principal at Statens Serum Institute

61 year

Health Technology

Consumer Services

Finance

Active connections

Name	Gender	Age	Linked companies	Collaboration
Sylvie Grégoire	M	62	NOVO NORDISK A/S	9 years
Poul Rødbroe Rasmussen	M	-	Statens Serum Institute	-
Mette Agger	F	59	Statens Serum Institute	-
Niels Borregaard	M	73	University of Copenhagen	26 years
Doug Langa	M	58	NOVO NORDISK A/S	13 years
Stephen Gough	M	-	NOVO NORDISK A/S	9 years

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Laura Spalding	F	-	EffRx, Inc. EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co.	-
Christer Rosén	M	72	EffRx, Inc. EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co.	13 years
Mats Gunnar Pettersson	M	78	H. LUNDBECK A/S	10 years
Henrik Ramlau-Hansen	M	67	University of Copenhagen	9 years
Kåre Schultz	M	62	University of Copenhagen NOVO NORDISK A/S	28 years
Kim Vilbour Andersen	M	-	University of Copenhagen	5 years
Peter Henrik Kürstein-Jensen	M	68	H. LUNDBECK A/S	11 years
Jacob Tolstrup	M	52	H. LUNDBECK A/S	25 years
Jacob Uittenbogaard	M	-	EffRx, Inc. EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co.	-
Nikolai Søren Kirkby	M	-	University of Copenhagen	4 years
Jesper Nerlov	M	56	University of Copenhagen	8 years
Lykke Friis	M	54	University of Copenhagen	10 years
Peter Andersen	M	67	H. LUNDBECK A/S	-
Thomas Dywremose	M	-	University of Copenhagen	6 years
Ana de Jesus-Johansson	F	-	EffRx, Inc. EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co.	-
Lars Christian Lassen	M	-	NOVO NORDISK A/S	-
Jakob Riis	M	58	University of Copenhagen	5 years
Martin Jensen	M	64	University of Copenhagen	10 years
Anne Prener	M	66	NOVO NORDISK A/S	12 years
Jesper Alling Coverdale Kofoed	M	-	University of Copenhagen	7 years
Bratanata Perdana	M	55	Seattle University	5 years
Soren Mogelsvang	M	52	University of Copenhagen	6 years
Thomas Price	M	68	SANUWAVE HEALTH, INC.	1 years
Jesper Parnevik	M	-	EffRx, Inc. EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co.	13 years
Jørn Møller Mayntzhusen	M	58	H. LUNDBECK A/S	-
Kurt Anker Nielsen	M	78	NOVO NORDISK A/S	13 years
Hannu Ragnvald Ryöppönen	M	72	NOVO NORDISK A/S	6 years
Claus Tycho Bræstrup	M	79	H. LUNDBECK A/S	10 years
Alan Rubino	M	69	SANUWAVE HEALTH, INC.	18 years
Helge Lund	M	61	NOVO NORDISK A/S	1 years
Mary Szela	F	60	NOVO NORDISK A/S	3 years
Lise Kingo	F	62	NOVO NORDISK A/S	26 years
Eva Steiness	M	83	H. LUNDBECK A/S	9 years
Anders Gersel Pedersen	M	73	H. LUNDBECK A/S	18 years
Bruno Francois Jules Angelici	M	77	NOVO NORDISK A/S	6 years
Jeppe Fonager Christiansen	M	64	NOVO NORDISK A/S University of Copenhagen	1 years
Sten Scheibye	M	72	NOVO NORDISK A/S	10 years
Thomas Paul Koestler	M	71	NOVO NORDISK A/S	5 years
Liz Hewitt	F	67	NOVO NORDISK A/S	9 years
Jan Miller	M	54	H. LUNDBECK A/S	11 years
Jan Hoff	M	-	NOVO NORDISK A/S	-
Mikkel Dyhr Gadegaard	M	45	NOVO NORDISK A/S	4 years
Johan Kirstein Brammer	M	48	University of Copenhagen	3 years
Arthur Mangaratua Simatupang	M	51	Seattle University	4 years
Lone Fønss Schrøder	F	64	University of Copenhagen	3 years
Pamela Kirby	M	70	NOVO NORDISK A/S	3 years
Amy Elmendorf Tucker	F	-	Seattle University	3 years
Christoffer Erik Lorenzen	M	48	H. LUNDBECK A/S	5 years
Bjørn Høi Jensen	M	62	University of Copenhagen	1 years
Lida Skifte Lennert	F	52	University of Copenhagen	-
Karen Lauberg Lauritsen	F	56	NOVO NORDISK A/S	12 years
Eric J. Trimble	M	-	Seattle University	2 years
Hendry Leo	M	49	Seattle University	4 years
Michael Moyell Juul	M	50	University of Copenhagen	4 years
Morten Weicher Weicher	M	-	University of Copenhagen	-
Eivind Kolding	M	64	NOVO NORDISK A/S	-
Krisja Vermeylen	F	62	NOVO NORDISK A/S	3 years
Søren Toftgaard	M	48	University of Copenhagen	6 years
Shri Parikh	M	-	SANUWAVE HEALTH, INC.	2 years
Joan Schmidt	F	60	NOVO NORDISK A/S	20 years
Mozhgan Dorkhan	M	54	NOVO NORDISK A/S	6 years
Maria Jose Arce-Tomas	M	-	NOVO NORDISK A/S	4 years
Jes Trygved	M	51	H. LUNDBECK A/S	3 years
Claus S. Kallesoe	M	-	H. LUNDBECK A/S	14 years
Lars Nymann Andersen	M	52	University of Copenhagen	3 years
Else Sissel Vorstrup	M	-	H. LUNDBECK A/S	-
Matt Dhane	M	-	Seattle University	4 years
Christian Sagild	M	64	University of Copenhagen	1 years
Thomas E. Puzzo	M	57	Seattle University	3 years
Per Toft Valstorp	M	75	NOVO NORDISK A/S	14 years
Andreas Hasle	M	69	University of Copenhagen	4 years
Steve Orr	M	62	Seattle University	2 years
Peter Hugreffe Ankersen	M	-	NOVO NORDISK A/S	-
Terje Kalland	M	73	NOVO NORDISK A/S	6 years
Hans Henrik Munch-Jensen	M	64	H. LUNDBECK A/S	8 years
Thomas Dyrberg	M	69	University of Copenhagen	3 years
Nils Aage Brünner	M	72	University of Copenhagen	12 years
Ulrik Carstens	M	-	University of Copenhagen	6 years
Susanne L. Biltoft	F	61	University of Copenhagen	8 years
Haibin Zheng	M	-	University of Copenhagen	3 years
Charlotte Zarp-Andersson	F	-	NOVO NORDISK A/S	-
Jørgen Wedel	M	75	NOVO NORDISK A/S	12 years
Mette Carlstedt	F	56	H. LUNDBECK A/S	18 years
Jørgen Okkels Nielsen	M	76	H. LUNDBECK A/S	5 years
Henri Honoris	M	49	Seattle University	2 years
Mads Krogsgaard Thomsen	M	63	University of Copenhagen	8 years
Inge Holm Lauritzen	F	57	H. LUNDBECK A/S	9 years
Jesper Høiland	M	63	NOVO NORDISK A/S	8 years
Jesper Kløve	M	-	NOVO NORDISK A/S	-
Kåre Bo Stolt	M	60	University of Copenhagen	3 years
Jørgen Nergaard Gøl	M	-	University of Copenhagen	4 years
Karsten Witt	M	68	University of Copenhagen	3 years
Rasmus Lund	M	50	University of Copenhagen	5 years
Bradley Patricia	F	-	NOVO NORDISK A/S	2 years

Statistics

Country	Connections	% of total
Denmark	83	83.00%
United States	17	17.00%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections